Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Chad is experiencing a steady growth in demand due to various underlying factors.
Customer preferences: Chadian customers tend to prefer affordable and easily accessible anti-rheumatic drugs. Due to the high poverty rate in the country, expensive or branded drugs are not popular among the majority of the population. Additionally, many Chadians live in rural areas where access to healthcare facilities is limited. Therefore, customers tend to prefer drugs that can be easily obtained through local pharmacies or informal markets.
Trends in the market: The Anti-Rheumatic Drugs market in Chad has been growing steadily due to an increase in the prevalence of rheumatic diseases in the country. This increase can be attributed to factors such as urbanization, changes in lifestyle, and an aging population. As a result, there has been an increase in demand for anti-rheumatic drugs in the country. However, the market is still relatively small due to the limited healthcare infrastructure in the country.
Local special circumstances: Chad is a landlocked country with a low-income economy. The country faces various challenges such as political instability, poor infrastructure, and a high poverty rate. These factors have a significant impact on the healthcare sector in the country, including the Anti-Rheumatic Drugs market. The limited healthcare infrastructure in the country makes it challenging for patients to access healthcare facilities and obtain the necessary drugs. Additionally, the lack of regulations and monitoring in the market has led to the proliferation of counterfeit drugs, which poses a significant risk to patients.
Underlying macroeconomic factors: The Chadian economy is heavily dependent on oil exports, which account for the majority of the country's revenue. However, the decline in oil prices in recent years has had a significant impact on the economy, leading to a decline in government revenue and a decrease in public spending. This has had a negative impact on the healthcare sector, including the Anti-Rheumatic Drugs market. The limited resources and funding available have made it challenging to improve the healthcare infrastructure and provide access to affordable drugs for the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
